XML 212 R189.htm IDEA: XBRL DOCUMENT v3.19.1
Reportable segments (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue   $ 2,265,803 $ 2,157,323 $ 1,939,322
Cost of sales   (1,483,524) (1,394,822) (1,328,285)
Administrative expenses   (118,126) (101,171) (88,436)
Interest Expense $ (50,124) (59,914) (50,124) (57,498)
Depreciation and amortisation expense   (221,499) (240,526) (249,792)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   6,351 14,452 13,047
Income tax expense, continuing operations   178,975 166,173 132,965
Other items other than significant cash       0
Income (loss) before taxes   621,038 594,590 414,889
Net income (loss) from continuing operations   442,063 428,417 281,924
Net Income (Loss)   442,063 428,417 281,924
Assets   4,268,094 4,296,236 4,217,980
Equity-accounted investees   111,549 152,630 133,140
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts   (17,131) (42,879)  
Increase of non-current assets     0 (107,268)
Liabilities   2,130,292 2,048,768 1,910,708
Impairment loss recognized in profit or loss   (4,294) (31,899) (40,544)
Reversal of impairment losses recognized in profit or loss for the period   0 0 2,907
Cash flows from (used in) operating activities   524,839 758,272 633,662
Cash flows from (used in) investing activities   (187,004) (248,067) 162,386
Cash flows from (used in) financing activities   (387,313) (411,920) (816,410)
Operating Segments [Member]        
Revenue   2,265,803 2,157,323 1,939,322
Cost of sales   (1,483,524) (1,394,822) (1,328,285)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (221,499) (240,526) (249,681)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   782,279 762,501 611,037
Net income (loss) from continuing operations   782,279 762,501 611,037
Net Income (Loss)   782,279 762,501 611,037
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (7,279) (17,583) (949)
Reversal of impairment losses recognized in profit or loss for the period   0 0 2,907
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Unallocated amounts [member]        
Revenue     0 0
Cost of sales     0 0
Administrative expenses   (118,126) (101,171) (88,436)
Interest Expense   (59,914) (50,124) (57,498)
Depreciation and amortisation expense     0 (111)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   6,351 14,452 13,047
Income tax expense, continuing operations   (178,975) (166,173) (132,965)
Other items other than significant cash       0
Income (loss) before taxes   (161,241) (167,911) (196,148)
Net income (loss) from continuing operations   (340,216) (334,084) (329,113)
Net Income (Loss)   (340,216) (334,084) (329,113)
Assets   4,268,094 4,296,236 4,217,980
Equity-accounted investees   111,549 152,630 133,140
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts   (15,028) 0  
Increase of non-current assets     0 (107,268)
Liabilities   2,130,291 2,048,768 1,910,708
Impairment loss recognized in profit or loss   2,985 (14,316) (39,595)
Reversal of impairment losses recognized in profit or loss for the period   0 0 0
Cash flows from (used in) operating activities   5,241,839 758,272  
Cash flows from (used in) investing activities   (187,004) (248,067)  
Cash flows from (used in) financing activities   (387,313) (411,920)  
Specialty plant nutrients [Member]        
Revenue   781,750 697,251 623,853
Cost of sales   (613,267) (555,356) (478,074)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (73,073) (73,702) (89,864)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   168,483 141,895 145,779
Net income (loss) from continuing operations   168,483 141,895 145,779
Net Income (Loss)   168,483 141,895 145,779
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (2,227) (15,025) 0
Reversal of impairment losses recognized in profit or loss for the period   0 0 133
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Iodine and its derivatives [Member]        
Revenue   324,972 252,123 231,144
Cost of sales   (217,464) (199,808) (191,298)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (45,280) (44,252) (35,958)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   107,508 52,315 39,846
Net income (loss) from continuing operations   107,508 52,315 39,846
Net Income (Loss)   107,508 52,315 39,846
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (1,171) 335 0
Reversal of impairment losses recognized in profit or loss for the period   0 0 325
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Lithium and its derivatives [Member]        
Revenue   734,801 644,573 514,627
Cost of sales   (316,875) (189,242) (175,616)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (44,837) (18,036) (33,010)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   417,926 455,331 339,011
Net income (loss) from continuing operations   417,926 455,331 339,011
Net Income (Loss)   417,926 455,331 339,011
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (243) 1,112 (251)
Reversal of impairment losses recognized in profit or loss for the period   0 0 0
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Industrial chemicals [Member]        
Revenue   108,268 135,578 104,137
Cost of sales   (72,964) (91,753) (67,378)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (16,041) (16,050) (12,666)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   35,304 43,825 36,759
Net income (loss) from continuing operations   35,304 43,825 36,759
Net Income (Loss)   35,304 43,825 36,759
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (79) (3,546) 0
Reversal of impairment losses recognized in profit or loss for the period   0 0 233
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Potassium [Member]        
Revenue   267,474 379,326 403,323
Cost of sales   (217,386) (313,690) (359,477)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (41,891) (88,130) (67,571)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   50,088 65,636 43,846
Net income (loss) from continuing operations   50,088 65,636 43,846
Net Income (Loss)   50,088 65,636 43,846
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (3,006) (240) 0
Reversal of impairment losses recognized in profit or loss for the period   0 0 2,216
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Other products and services [Member]        
Revenue   48,538 48,472 62,238
Cost of sales   (45,568) (44,973) (56,442)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (377) (356) (10,612)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   2,970 3,499 5,796
Net income (loss) from continuing operations   2,970 3,499 5,796
Net Income (Loss)   2,970 3,499 5,796
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (553) (219) (698)
Reversal of impairment losses recognized in profit or loss for the period   0 0 0
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Reportable segments [member]        
Revenue   2,265,803 2,157,323 1,939,322
Cost of sales   (1,483,524) (1,394,822) (1,328,285)
Administrative expenses   0 0 0
Interest Expense   0 0 0
Depreciation and amortisation expense   (221,499) (240,526) (249,681)
The entity's interest in the profit or loss of associates and joint ventures accounted for by the equity method   0 0 0
Income tax expense, continuing operations   0 0 0
Other items other than significant cash       0
Income (loss) before taxes   782,279 762,501 611,037
Net income (loss) from continuing operations   782,279 762,501 611,037
Net Income (Loss)   782,279 762,501 611,037
Assets   0 0 0
Equity-accounted investees   0 0 0
Increase of non-current assets   0 0 0
Liabilities   0 0 0
Impairment loss recognized in profit or loss   (7,279) (17,583) (949)
Reversal of impairment losses recognized in profit or loss for the period   0 0 2,907
Cash flows from (used in) operating activities   0 0  
Cash flows from (used in) investing activities   0 0  
Cash flows from (used in) financing activities   0 0  
Parent [Member]        
Assets   3,737,892 3,658,528  
Liabilities   1,652,401 1,470,707  
Parent [Member] | Operating Segments [Member]        
Revenue   2,265,803 2,157,323 1,939,322
Parent [Member] | Unallocated amounts [member]        
Revenue     0 0
Parent [Member] | Specialty plant nutrients [Member]        
Revenue   781,750 697,251 623,853
Parent [Member] | Iodine and its derivatives [Member]        
Revenue   324,972 252,123 231,144
Parent [Member] | Lithium and its derivatives [Member]        
Revenue   734,801 644,573 514,627
Parent [Member] | Industrial chemicals [Member]        
Revenue   108,268 135,578 104,137
Parent [Member] | Potassium [Member]        
Revenue   267,474 379,326 403,323
Parent [Member] | Other products and services [Member]        
Revenue   48,538 48,472 62,238
Parent [Member] | Reportable segments [member]        
Revenue   2,265,803 2,157,323 1,939,322
Other Operating Segment [Member] | Operating Segments [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Unallocated amounts [member]        
Revenue   0 0 0
Other Operating Segment [Member] | Specialty plant nutrients [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Iodine and its derivatives [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Lithium and its derivatives [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Industrial chemicals [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Potassium [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Other products and services [Member]        
Revenue   0 0 0
Other Operating Segment [Member] | Reportable segments [member]        
Revenue   $ 0 $ 0 $ 0